Reaction
Trichodysplasia Spinulosa reporting signals
As of the last recalculation, Trichodysplasia Spinulosa appears in 372 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is TACROLIMUS OINTMENT 0.1% (PRR 626.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tacrolimus Ointment 0.1% | 294 | 626.2 | 627.7 |
| Tacrolimus Extended-Release Capsules | 294 | 624.5 | 626.0 |
| Tacrolimus | 301 | 559.1 | 560.2 |
| Mycophenolate Mofetil Hydrochloride | 234 | 257.7 | 258.1 |
| Mycophenolate Mofetil | 233 | 255.2 | 255.6 |
| Mycophenilic Acid | 41 | 124.3 | 124.5 |
| Mycophenolic Acid | 50 | 100.8 | 101.0 |
| Anti-Thymocyte Globulin (Rabbit) | 12 | 86.0 | 86.1 |
| Valganciclovir Hydrochloride Powder, | 16 | 76.7 | 76.8 |
| Basiliximab | 14 | 69.2 | 69.3 |
| Everolimus Tablets | 18 | 63.1 | 63.1 |
| Valganciclovir | 17 | 52.8 | 52.9 |
| Valganciclovir Hydrochloride | 17 | 52.8 | 52.9 |
| Mercaptopurine | 15 | 50.4 | 50.4 |
| Sirolimus | 10 | 42.6 | 42.7 |